TBK1 and metabolic dysfunction-associated steatotic liver disease: Recent clinical studies have also shown that IKKε/TBK1 inhibitor can improve hepatic steatosis and insulin sensitivity in obese patients with non-alcoholic fatty liver disease (NAFLD) and T2D17.